An engineered concealed IL-15-R elicits tumor-specific CD8(+)T cell responses through PD-1-cis delivery

Checkpoint blockade immunotherapy releases the inhibition of tumor-infiltrating lymphocytes (TILs) but weakly induces TIL proliferation. Exogenous IL-15 could further expand TILs and thus synergize with αPD-L1 therapy. However, systemic delivery of IL-15 extensively expands peripheral NK cells, caus...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Jiao, Zou, Zhuangzhi, Guo, Jingya, Cai, Yueqi, Xue, Diyuan, Liang, Yong, Wang, Wenyan, Peng, Hua, Fu, Yang-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2022
Materias:
Brief Definitive Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521244/
https://www.ncbi.nlm.nih.gov/pubmed/36165896
http://dx.doi.org/10.1084/jem.20220745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521244/
https://www.ncbi.nlm.nih.gov/pubmed/36165896
http://dx.doi.org/10.1084/jem.20220745

Ejemplares similares